COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs -
COMMUNIQUÉ DE PRESSE
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024 -
COMMUNIQUÉ DE PRESSE
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone)
Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030 -
-
COMMUNIQUÉ DE PRESSE
Board-Certified and Highly Accomplished, Active Duty Military Ophthalmologist Now Treating Patients at LasikPlus Louisville
Kentucky-based ophthalmologist Dr. Gregory Bryant Giles, known for his expertise in LASIK and cataract surgery, is now treating patients at LasikPlus Louisville vision center -
COMMUNIQUÉ DE PRESSE
E-PASS Customers Can Save on Monthly Bill as Part of State’s Toll Relief Program
E-PASS customers can now save 50% on monthly toll bills starting April 1, thanks to the statewide toll relief program announced by Gov. Ron DeSantis. Discounts applicable to two-axle vehicles with 35+ trips monthly -
COMMUNIQUÉ DE PRESSE
CO2 GRO Inc. Announces the Commissioning of Its Largest Global Commercial Project with Hidroexpo
CO2 GRO Inc. successfully installs & commissions its largest commercial project at Hidroexpo's greenhouse complex in El Salvador, enhancing pepper production with aqueous COâ‚‚ enrichment technology -
-
